Targeting BCMA with bispecific antibodies in R/R myeloma

Novel BCMA-targeting therapies to treat TCE relapsed/refractory multiple myelomaПодробнее

FAQs on Non-BCMA-Targeted Bispecific Antibodies in Multiple MyelomaПодробнее

The impact of prior BCMA CAR-T therapy on the efficacy BCMA-targeting bispecifics in myelomaПодробнее

REGN5459, a BCMA×CD3 bispecific antibody, in R/R multiple myelomaПодробнее

Using BCMA-targeting agents in earlier lines of treatment for multiple myelomaПодробнее

Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer InstituteПодробнее

Safety & efficacy of cevostamab in patients with heavily pre-treated R/R multiple myelomaПодробнее

LINKER-MM1: linvoseltamab, a bispecific antibody, in R/R multiple myelomaПодробнее

Dual-targeting bispecific antibody alnuctamab in R/R multiple myelomaПодробнее

Role of BCMA-targeting ADCs in the management of myelomaПодробнее

Managing progression after BCMA-targeted therapy in R/R multiple myelomaПодробнее

Phase I trial of a BCMA-CD3 bispecific antibody in R/R myelomaПодробнее

ASCO 2022: ZUMA-2, BCMA-targeting BiTEs & novel CARs in myelomaПодробнее

Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) in R/R MMПодробнее

The importance of BCMA-targeting ADCs and bispecific antibodies in R/R multiple myelomaПодробнее

BCMA/CD38 CAR-T for R/R MM: promising trial resultsПодробнее

Phase I study of TNB-383B in R/R multiple myelomaПодробнее

How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myelomaПодробнее

Clinical advances with CAR-Ts and bispecifics in R/R myelomaПодробнее

Bispecific antibodies for myeloma: highlights from ASH 2020Подробнее